House health panel advances bills on price transparency, illicit drugs

Traders Union
All News
Financial News
House health panel bills

Highlights

House Energy and Commerce health panel advanced the Lower Costs, More Transparency Act, requiring hospitals and providers to publicly post standardized service prices.
Proposed legislation introduces new disclosure requirements for commercial and Medicare Advantage plans, including transparency on prior authorization approvals, and insurer premium-dollar allocation.
The panel advanced the Combatting Illicit Xylazine Act to classify xylazine as a Schedule III substance and is considering bills addressing fentanyl testing and community health center funding.

Markup agenda spans transparency and drug policy

As reported by the House Committee on Energy and Commerce, Subcommittee Chairman Morgan Griffith says the markup is intended to lower health care costs and safeguard communities through legislation on pricing, insurance oversight and illicit drugs.

Griffith says the package builds on a recent hearing on price transparency and on Trump administration initiatives aimed at making the health system more transparent. He also ties the effort to earlier subcommittee work on the HALT Fentanyl Act and the SUPPORT for Patients and Communities Reauthorization Act, which he says President Trump signed into law last year.

Among the measures under consideration is the Lower Costs, More Transparency Act, which Griffith says continues transparency work from the last Congress. He says the bill would codify regulations implemented by the Trump administration, require hospitals and providers to post service prices publicly, and standardize how those charges and services are disclosed.

Other bills would add disclosure requirements for commercial and Medicare Advantage plans, including prior authorization data showing the share of claims approved and denied in a plan year. Griffith also points to legislation focused on premium-dollar transparency, saying it is meant to show consumers how insurers spend premiums and how much goes to beneficiary care rather than administration or profit.

Cost pressures and regional health implications

Griffith says high health care costs remain a central challenge for patients, families and employers, while limited price visibility leaves consumers making care decisions without clear information on provider networks, treatment alternatives or likely bills. He argues that greater transparency could help counter the effects of consolidation among insurers and providers, which he says continues to reduce competition and push up prices.

On illicit drugs, Griffith says several bills continue the subcommittee's focus on the issue. He highlights the Combatting Illicit Xylazine Act, which would classify xylazine as a Schedule III substance under the Controlled Substances Act while preserving its legitimate use in large-animal veterinary medicine, and says the matter is significant in Virginia's Ninth District because of its cattle industry and two veterinary schools.

He also highlights Tyler's Law, which would require the Department of Health and Human Services to study and issue guidance on whether hospitals should include fentanyl testing in routine emergency department drug screens. In addition, Griffith says lawmakers are considering community health center bills, including one led by Vice Chairwoman Harshbarger that would allow some funding to support nutrition education and chronic disease prevention initiatives.

Our earlier report on the June 24 Joint Economic Committee hearing on waste, fraud and oversight gaps in Medicare and Medicaid outlined how lawmakers and experts argued that misaligned payment incentives and weak controls keep driving higher program spending. The discussion emphasized that while AI and analytics can improve detection, deeper structural reforms, stronger data sharing, and tougher oversight are needed to reduce inefficiency and protect taxpayer funds.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.